Features | Partner Sites | Information | LinkXpress
Sign In
SEEGENE
AB Sciex
FOCUS DIAGNOSTICS, INC.

Newest Combination HIV Antigen-Antibody Assay Evaluated

By Labmedica International staff writers
Posted on 27 Feb 2013
Diagnostic tests capable of early detection represent the most effective means of preventing transmission of human immunodeficiency virus (HIV).

A fourth-generation antigen-antibody combination assay has been developed to allow earlier detection of seroconversion, and has increased sensitivity and improved specificity.

Scientists at the Innsbruck University Hospital (Austria) determined how early the assay could detect infection compared with existing assays; whether all HIV variants could be detected; and the assay's specificity using samples from blood donors, routine specimens, and patients with potential cross-reacting factors.

The study was carried out at 12 centers in Europe, Thailand, and Australia. The Elecsys HIV combi PT assay (Roche Diagnostics; Penzberg, Germany) is performed according to the sandwich principle. The results are automatically determined by the Elecsys software that compares the signal produced from the sample with the cutoff value obtained during system calibration. The total assay time is 27 minutes.

A total of 14 seroconversion panels, comprising 135 samples were analyzed to determine how soon after a positive polymerase chain reaction (PCR) result the immunoassays could detect HIV infection. Samples were identified as positive by the Elecsys assay 4.9 days after a positive PCR result that had been predetermined, which was earlier than the 5.3 to 7.1days observed with other comparable assays. The analytical sensitivity of the Elecsys HIV combi PT assay for the HIV-1 p24 antigen was 1.05 IU/mL, which compares favorably with the other assays.

In addition, the assay identified all screened HIV subtypes and displayed greater sensitivity to HIV-2 homologous antigen and antibodies to HIV-1 E and O and HIV-2 than the other assays. The assay demonstrated 100% specificity in patients with infections other than HIV, such as Cytomegalovirus or herpes simplex virus. Overall, the specificity of the Elecsys assay was 99.88% using samples from blood donors and 99.81% when analyzing unselected samples. Potential cross-reacting factors did not interfere with assay performance. The Elecsys HIV combi PT assay has been granted the European Conformity (CE) marking and is now available for use in laboratory-based testing. The study was published in the February 2013 issue of the journal Medical Microbiology and Immunology.

Related Links:
Innsbruck University Hospital
Roche Diagnostics


PURITAN MEDICAL
GREINER-BIO-ONE
ADVANCED INSTRUMENTS
BioConferenceLive

Channels

Genetic Tests

view channel
Image: The QuantiTect Reverse Transcription Kit (Photo courtesy of Qiagen)

Blood Tests Predict Risk of Sudden Cardiac Death

A simple blood test can predict a person's risk for sudden cardiac death, enabling physicians to quickly and accurately assess a patient's need for an implantable cardiac defibrillator (ICD).... Read more

Hematology

view channel

Blood Donations Screened for Viruses Using Multiplex Assay

A global healthcare company was chosen to partner the Japanese Red Cross (JRC; Tokyo, Japan) for nucleic acid screening of the nation's blood supply. Under the terms of the 7-year agreement, the healthcare company, Grifols (Barcelona, Spain) will provide the JRC with its newest automation platform, the Procleix Panther... Read more

Pathology

view channel

Gene Profile Predicts Risk of Bladder Cancer Recurrence

A genomic study has pinpointed several markers that identify bladder cancer patients at risk of recurrence and that may be indicators of overall survival status. Nearly half of patients with bladder cancer experience recurrences, so reliable predictors of this recurrent phenotype are needed to guide surveillance and treatment.... Read more

Industry News

view channel

Beckman Coulter and hc1.com Enter Strategic Partnership for Innovative Healthcare Cloud System

The diagnostics division of Beckman Coulter (Brea, CA, USA) and hc1.com (Indianapolis, IN, USA) have announced a partnership to bring an innovative healthcare cloud-technology system to clinical laboratories. The system, hc1.com's "Healthcare Relationship Cloud," helps turn large amounts of clinical data into actionable... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.